JP2014510518A - Ｈｓａ関連組成物および使用方法 - Google Patents

Ｈｓａ関連組成物および使用方法 Download PDF

Info

Publication number
JP2014510518A
JP2014510518A JP2013553420A JP2013553420A JP2014510518A JP 2014510518 A JP2014510518 A JP 2014510518A JP 2013553420 A JP2013553420 A JP 2013553420A JP 2013553420 A JP2013553420 A JP 2013553420A JP 2014510518 A JP2014510518 A JP 2014510518A
Authority
JP
Japan
Prior art keywords
residue
hsa
amino acid
polypeptide
domain iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013553420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510518A5 (OSRAM
Inventor
ガオ，チャンショウ
チャウダリー，チェティ
ヤオ，シャオタオ
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/024855 external-priority patent/WO2011103076A1/en
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2014510518A publication Critical patent/JP2014510518A/ja
Publication of JP2014510518A5 publication Critical patent/JP2014510518A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013553420A 2011-02-15 2011-08-09 Ｈｓａ関連組成物および使用方法 Pending JP2014510518A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US2011/024855 2011-02-15
PCT/US2011/024855 WO2011103076A1 (en) 2010-02-16 2011-02-15 Hsa-related compositions and methods of use
PCT/US2011/047040 WO2012112188A1 (en) 2011-02-15 2011-08-09 Hsa-related compositions and methods of use

Publications (2)

Publication Number Publication Date
JP2014510518A true JP2014510518A (ja) 2014-05-01
JP2014510518A5 JP2014510518A5 (OSRAM) 2014-09-04

Family

ID=46675795

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013553420A Pending JP2014510518A (ja) 2011-02-15 2011-08-09 Ｈｓａ関連組成物および使用方法

Country Status (7)

Country Link
EP (1) EP2675471A4 (OSRAM)
JP (1) JP2014510518A (OSRAM)
KR (1) KR20140012094A (OSRAM)
CN (1) CN103379915A (OSRAM)
AU (1) AU2011359378A1 (OSRAM)
CA (1) CA2826683A1 (OSRAM)
WO (1) WO2012112188A1 (OSRAM)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
JP2013509170A (ja) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ アルブミン変異体
ES2678144T3 (es) * 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
CN103649123B (zh) 2011-06-13 2017-05-24 Csl有限公司 抗g‑csfr抗体及其用途
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
WO2013135896A1 (en) 2012-03-16 2013-09-19 Novozymes Biopharma Dk A/S Albumin variants
RU2670063C2 (ru) * 2012-11-08 2018-10-17 Альбумедикс А/С Варианты альбумина
EP2956002B1 (en) 2013-02-16 2017-09-06 Albumedix A/S Pharmacokinetic animal model
CN105209482B (zh) * 2013-03-15 2022-04-29 阿菲博迪公司 新的多肽
PL3007717T3 (pl) * 2013-06-12 2018-12-31 Pharis Biotec Gmbh Peptydy o antagonistycznej aktywności w stosunku do naturalnego CXCR4
WO2015036579A1 (en) * 2013-09-13 2015-03-19 Novozymes Biopharma Dk A/S Albumin variants
CA2928700C (en) * 2013-11-01 2019-01-15 University Of Oslo Albumin variants and uses thereof
KR20240093725A (ko) 2015-03-12 2024-06-24 메디뮨 엘엘씨 알부민 융합 단백질의 정제 방법
EP3337816B1 (en) 2015-08-20 2024-02-14 Albumedix Ltd Albumin variants and conjugates
JP6893504B2 (ja) * 2015-09-23 2021-06-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 速い解離速度を有する血清アルブミン結合フィブロネクチンタイプｉｉｉドメイン
CA3005953A1 (en) 2015-12-22 2017-06-29 Albumedix Ltd Improved protein expression strains
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
CN110337590A (zh) 2016-11-04 2019-10-15 奥胡斯大学 以新生儿Fc受体过表达为特征的肿瘤的识别和治疗
EP4026908A1 (en) 2017-06-20 2022-07-13 Albumedix Ltd Improved protein expression strains
ES2939461T3 (es) 2017-11-29 2023-04-24 Csl Ltd Método para tratar o prevenir la lesión por isquemia-reperfusión
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
KR102854142B1 (ko) 2018-05-16 2025-09-04 시에스엘 리미티드 가용성 보체 수용체 1형 변이체 및 이의 용도
BR112021008105A2 (pt) 2018-10-29 2021-08-03 Biogen Ma Inc. variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica
MX2022002638A (es) 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
CN114478800B (zh) * 2021-02-05 2022-10-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
CN113912730B (zh) * 2021-12-14 2022-03-04 北京科诺信诚科技有限公司 缓释的抗FcRn抗体或抗原结合片段及其应用
EP4608448A1 (en) 2022-10-28 2025-09-03 Aarhus Universitet Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025007195A1 (en) 2023-07-05 2025-01-09 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025158071A1 (en) 2024-01-26 2025-07-31 Sartorius Albumedix Limited Retroviral preparations containing albumin for enhancing transduction efficiency, uses thereof for cell transduction

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509581A (ja) * 1994-03-05 1997-09-30 デルタ、バイオテクノロジー、リミテッド 酵母株および修飾アルブミン
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
WO2009126920A2 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010118169A2 (en) * 2009-04-08 2010-10-14 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
JP2013519392A (ja) * 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509581A (ja) * 1994-03-05 1997-09-30 デルタ、バイオテクノロジー、リミテッド 酵母株および修飾アルブミン
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
WO2009126920A2 (en) * 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010118169A2 (en) * 2009-04-08 2010-10-14 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
JP2013519392A (ja) * 2010-02-16 2013-05-30 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JPN5013002679; ＫＥＮＡＮＯＶＡ　Ｖ: 'ＨＳＡ　ＤＯＭＡＩＮ　ＩＩＩ　ＡＳ　Ａ　ＰＲＯＴＥＩＮ　ＳＣＡＦＦＯＬＤ　ＷＩＴＨ　ＤＥＦＩＮＥＤ　ＳＥＲＵＭ　ＰＨＡＲＭＡＣＯＫＩＮＥＴＩＣＳ' ＴＨＥ　ＪＯＵＲＮＡＬ　ＯＦ　ＮＵＣＬＥＡＲ　ＭＥＤＩＣＩＮＥ　［ＯＮＬＩＮＥ］ Ｖ５０　Ｎ　ＳＵＰＰＬ．　２, 20090515 *
JPN6015001884; Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ，　２００７，　Ｖｏｌ．１７７４，　ｐ．１５８２-１５９０ *
JPN6015001889; Ｂｉｏｃｈｅｍｉｓｔｒｙ，　２００６，　Ｖｏｌ．４５，　ｐ．４９８３-４９９０ *
JPN6015031392; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ．　ＵＳＡ ｖｏｌ．８４, 1987, ｐｐ．４４１３-４４１７ *
JPN6015031395; Ｐｒｏｔｅｉｎ　Ｅｎｇｉｎｅｅｒｉｎｇ ｖｏｌ．１２　ｎｏ．６, 1999, ｐｐ．４３９-４４６ *

Also Published As

Publication number Publication date
WO2012112188A1 (en) 2012-08-23
EP2675471A1 (en) 2013-12-25
CA2826683A1 (en) 2012-08-23
EP2675471A4 (en) 2015-01-28
AU2011359378A1 (en) 2013-10-03
KR20140012094A (ko) 2014-01-29
CN103379915A (zh) 2013-10-30

Similar Documents

Publication Publication Date Title
JP2014510518A (ja) Ｈｓａ関連組成物および使用方法
CN102781960B (zh) Hsa相关组合物及使用方法
US9045564B2 (en) HSA-related compositions and methods of use
US20210122805A1 (en) Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS
EP2443155B1 (en) Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1 (mtm1) polypeptides
TWI526220B (zh) Ｆｇｆ２１突變體及其用途
AU2013315482B2 (en) Fibronectin based scaffold domain proteins that bind to myostatin
CA2901978A1 (en) Methods and compositions for treatment of pompe disease
US10781433B2 (en) Methods and compositions for treatment of Lafora disease
EP3355908A1 (en) Treatment of bile acid disorders
US20210395716A1 (en) Methods and compositions for treatment of protein aggregation-based disorders
HK1169663B (en) Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1 (mtm1) polypeptides
HK1169663A (en) Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularin 1 (mtm1) polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140717

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160419